BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
- Clinical outcomes and quality of life measures for acoramidis in variant ATTR-CM - Post-hoc analysis showing lower incidence of atrial fibrillation events - Data on serum TTR levels in both wild-type and variant ATTR-CM patients - Real-world disease progression studies - Analysis of ATTR-CM diagnosis timelines - Mortality cause analysis from the ATTRibute-CM study
The presentations feature research from leading medical institutions including University College London, Stanford University, and the University of Montreal.- Risultati clinici e misure della qualità della vita per acoramidis nella variante ATTR-CM
- Analisi post-hoc che mostra una minore incidenza di episodi di fibrillazione atriale
- Dati sui livelli sierici di TTR in pazienti con ATTR-CM di tipo wild-type e variante
- Studi sulla progressione della malattia nel mondo reale
- Analisi dei tempi di diagnosi dell'ATTR-CM
- Analisi delle cause di mortalità dallo studio ATTRibute-CM
- Resultados clínicos y medidas de calidad de vida para acoramidis en ATTR-CM variante
- Análisis post-hoc que muestra una menor incidencia de eventos de fibrilación auricular
- Datos sobre los niveles séricos de TTR en pacientes con ATTR-CM de tipo salvaje y variante
- Estudios sobre la progresión de la enfermedad en el mundo real
- Análisis de los tiempos de diagnóstico de ATTR-CM
- Análisis de las causas de mortalidad del estudio ATTRibute-CM
- 변이형 ATTR-CM에서 아코라미디스의 임상 결과 및 삶의 질 평가
- 심방세동 사건 발생률 감소를 보여주는 사후 분석
- 야생형 및 변이형 ATTR-CM 환자의 혈청 TTR 수치 데이터
- 실제 임상에서의 질병 진행 연구
- ATTR-CM 진단 시기 분석
- ATTRibute-CM 연구에서의 사망 원인 분석
- Résultats cliniques et mesures de la qualité de vie pour acoramidis dans l'ATTR-CM variant
- Analyse post-hoc montrant une incidence réduite des événements de fibrillation auriculaire
- Données sur les niveaux sériques de TTR chez les patients ATTR-CM de type sauvage et variant
- Études sur la progression de la maladie en conditions réelles
- Analyse des délais de diagnostic de l'ATTR-CM
- Analyse des causes de mortalité issues de l'étude ATTRibute-CM
- Klinische Ergebnisse und Lebensqualitätsmessungen für Acoramidis bei der Varianten-ATTR-CM
- Post-hoc-Analyse, die eine geringere Inzidenz von Vorhofflimmern zeigt
- Daten zu Serum-TTR-Spiegeln bei Patienten mit Wildtyp- und Varianten-ATTR-CM
- Studien zum Krankheitsverlauf in der realen Welt
- Analyse der Diagnosezeiträume von ATTR-CM
- Analyse der Todesursachen aus der ATTRibute-CM-Studie
- None.
- None.
PALO ALTO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire abstract and two moderated ePosters on the clinical outcomes and quality of life measures provided by acoramidis in variant transthyretin amyloid cardiomyopathy (ATTR-CM) and one moderated ePoster on a post-hoc analysis of the lower incidence rate of atrial fibrillation-related events in patients with ATTR-CM, all from the ATTRibute-CM study will be shared at the Annual Congress of the Heart Failure Association of the ESC (Heart Failure 2025), taking place in Belgrade, Serbia on May 17 - 20, 2025.
In addition to the four abstracts, three moderated ePosters will be shared on the disease progression of ATTR-CM in a real-world setting, a retrospective cohort study on manifestation to diagnosis of ATTR-CM, and data on the cause of death of ATTR-CM patients in the ATTRibute-CM study.
Rapid-fire Abstract
Acoramidis Improves Serum TTR Levels in Patients with Wild-type or Variant Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CM
Presenter: Anique Ducharme, M.D., Université de Montréal, CAN
Date: Tuesday, May 20 at 8:30 am CEST/2:30 am ET
Moderated ePosters:
Effect of Acoramidis on Functional Capacity and Quality of Life in Patients with Variant ATTR-CM: Results from ATTRibute-CM
Presenter: Marianna Fontana, M.D., University College London, UK
Date: Sunday, May 18 at 11:00 am CEST/5:00 am ET
Effect of Acoramidis on All-cause Mortality, Cardiovascular Hospitalization and NT-proBNP in Variant ATTR-CM: Results from ATTRibute-CM
Presenter: Marianna Fontana, M.D., University College London, UK
Date: Sunday, May 18 at 11:00 am CEST/5:00 am ET
Acoramidis Treatment Is Associated with a Lower Incidence of Atrial Fibrillation-related Events in Patients with ATTR-CM: A Post Hoc Analysis of the ATTRibute-CM trial
Presenter: Kevin Alexander, M.D., Stanford University School of Medicine, USA
Date: Sunday, May 18 at 11:00 am CEST/5:00 am ET
Disease Progression Among Patients Receiving Tafamidis for ATTR-CM in a Real-world Setting
Presenter: Daniel P. Judge, M.D., Medical University of South Carolina, USA
Date: Sunday, May 18 at 11:00 am CEST/5:00 am ET
Cause of Death in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Findings from the ATTRibute-CM study
Presenter: Laura Obici, M.D., University of Pavia, ESP
Date: Sunday, May 18 at 11:00 am CEST/5:00 am ET
Time from First Recorded Clinical Manifestation to Diagnosis of Transthyretin Amyloid Cardiomyopathy: A Retrospective Cohort Study Using U.S. Claims Data
Presenter: Joshua Mitchell, M.D., Washington University School of Medicine in St. Louis, USA
Date: Sunday, May 18 at 11:00 am CEST/5:00 am ET
About Attruby™ (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (
About BridgeBio
BridgeBio Pharma (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, and YouTube.
BridgeBio Media Contact:
Bubba Murarka, EVP Communications
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, VP Strategic Finance
ir@bridgebio.com
FAQ
What will BridgeBio (BBIO) present at Heart Failure 2025 regarding acoramidis?
When and where is BridgeBio's (BBIO) Heart Failure 2025 presentation scheduled?
What are the key findings from BBIO's ATTRibute-CM study being presented?
Who are the main presenters for BridgeBio's ATTRibute-CM study results?
